1. [(18)F]fluciclovine PET/CT for Preoperative Staging in Patients With Intermediate to High-risk Primary Prostate Cancer
- Author
-
Alemozaffar, Mehrdad, Akintayo, Akinyemi A, Abiodun-Ojo, Olayinka A, Patil, Dattatraya, Saeed, Faisal, Huang, Yijian, Osunkoya, Adeboye O., Goodman, Mark M, Sanda, Martin, and Schuster, David M
- Subjects
Male ,Positron Emission Tomography Computed Tomography ,Preoperative Period ,Carboxylic Acids ,Humans ,Prostatic Neoplasms ,Prospective Studies ,Middle Aged ,Neoplasm Metastasis ,Article ,Cyclobutanes ,Aged ,Neoplasm Staging - Abstract
PURPOSE: Accurate preoperative staging of prostate cancer (PCa) is essential for treatment planning. Conventional imaging (CI) is limited in detection of metastases. Our primary aim was to determine if [(18)F]fluciclovine PET/CT is an early indicator of sub-clinical metastasis among patients with high-risk PCa. MATERIALS AND METHODS: 68 patients with unfavorable intermediate to very high-risk PCa without systemic disease on CI were recruited before robotic radical prostatectomy with extended pelvic lymph node dissection (EPLND). Diagnostic performance of [(18)F]fluciclovine PET/CT and CI for detection of metastatic disease, and correlation of positivity to node and metastatic deposit size were determined. RESULTS: 57/68 patients completed the protocol, of which 31/57 had nodal metastasis on histology. [(18)F]fluciclovine PET/CT sensitivity and specificity in detecting nodal metastasis were 55.3% and 84.8% per-patient, 54.8% and 96.4% per-region (right and left pelvis, presacral and non-regional), respectively. Compared with CI, [(18)F]fluciclovine PET/CT had significantly higher sensitivity on patient-based (55.3% vs 33.3%; p
- Published
- 2020